Drug Type Small molecule drug |
Synonyms (1-Hydroxyethylene)diphosphonic acid, (1-Hydroxyethylidene)bis(phosphonic acid), (1-Hydroxyethylidene)bisphosphonic acid + [35] |
Target |
Mechanism Bone resorption factor inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Sep 1977), |
RegulationOrphan Drug (EU) |
Molecular FormulaC2H8O7P2 |
InChIKeyDBVJJBKOTRCVKF-UHFFFAOYSA-N |
CAS Registry2809-21-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00314 | Etidronate Disodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | JP | 10 Jul 1996 | |
Ossification, Heterotopic | JP | 28 Sep 1990 | |
Osteitis Deformans | CA | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fahr's Disease | Phase 2 | NL | 03 Apr 2023 | |
HEM Dysplasia | Phase 2 | NL | 03 Apr 2023 | |
Osteoporosis | Phase 2 | US | 01 Sep 1977 | |
ABCC6 deficiency | Preclinical | EU | 11 Oct 2022 | |
Osteoporosis | Preclinical | US | 01 Sep 1977 |
Phase 2 | 7 | MRI Scan+Etidronate | mxoctjlagc(khpjmsllkj) = ppaxekbtdw kqustvmypr (jfougcdacz, osipokpcix - xpkcqclwtx) View more | - | 04 Oct 2022 | ||
Not Applicable | Chronic glomerulonephritis | Glucocorticoid-induced osteoporosis N-terminal telopeptide of type I collagen (NTx) | uncarboxylated osteocalcin (ucOC) | 43 | zsotxlsvuw(qbcrjzpwbe) = There were no significant differences in BMD between these groups during the study bgoftxpefu (ugigoigufe ) | Positive | 05 Nov 2013 | ||
Not Applicable | 50 | HRT | txsaeswggy(dmmoaxlsxa) = iihmnrrdot khnzjqqwqs (rtnjbxchqi ) | - | 01 Feb 2009 | ||
txsaeswggy(dmmoaxlsxa) = tzbdpzpibd khnzjqqwqs (rtnjbxchqi ) |